{
    "id": 2656,
    "fullName": "BRCA1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BRCA1 dec exp indicates decreased expression of the Brca1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 672,
        "geneSymbol": "BRCA1",
        "terms": [
            "BRCA1",
            "BRCAI",
            "BRCC1",
            "BROVCA1",
            "FANCS",
            "IRIS",
            "PNCA4",
            "PPP1R53",
            "PSCP",
            "RNF53"
        ]
    },
    "variant": "dec exp",
    "createDate": "11/30/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2878,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1 knockdown enhanced growth inhibition by Ambochlorin (chlorambucil) in triple-receptor negative breast cancer cell lines in culture (PMID: 25193512).",
            "molecularProfile": {
                "id": 2485,
                "profileName": "BRCA1 dec exp"
            },
            "therapy": {
                "id": 3035,
                "therapyName": "Chlorambucil",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2870,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of BRCA1 increased sensitivity of triple-negative breast cancer cells to Platinol (cisplatin) under hypoxic conditions (PMID: 25193512).",
            "molecularProfile": {
                "id": 2485,
                "profileName": "BRCA1 dec exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6148,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22726,
                "profileName": "BRCA1 dec exp MET dec exp"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6150,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22729,
                "profileName": "BRCA1 dec exp MET over exp"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2485,
            "profileName": "BRCA1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2486,
            "profileName": "BRCA1 dec exp CDK12 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10714,
            "profileName": "BRCA1 dec exp ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22726,
            "profileName": "BRCA1 dec exp MET dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22729,
            "profileName": "BRCA1 dec exp MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29575,
            "profileName": "BRCA1 dec exp GPBP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}